Navigation Links
Good News for HIV Patients Also Suffering From Hepatitis C Virus

Researchers conducting a large clinical trial of people infected with both HIV and hepatitis C have some positive news to report. // According to their study, patients who are treated with a newer combination of drugs are significantly more likely to rid their bodies of HCV than those who receive standard therapy.

The finding is important because as many as 300,000 of the estimated 1 million Americans infected with HIV also have HCV, and as people live longer with HIV, HCV is becoming a serious health problem.

The multinational study compared treatment with the drugs peginterferon alfa-2a (Pegasys) and ribavirin (Copegus) to treatment with the older treatment of interferon (Roferon-A) and ribavirin. Results showed the Pegasys-ribavirin combo was 40-percent effective in reducing HCV RNA to undetectable levels, compared to 12 percent for the older treatment. The drugs were even more effective in patients with the HCV genotypes 2 and 3, reaching 62-percent effectiveness. Patients with these genotypes who were on interferon-ribavirin saw a 36-percent effectiveness rate.The Pegasys-ribavirin combination in patients with genotype 1, typically the most difficult to treat HCV genotype, was 29-percent effective. This compares to an effectiveness of 7 percent among those taking interferon-ribavirin.

Researchers say the results of this study are groundbreaking news for the hundreds of thousands of Americans who are living with both hepatitis C and HIV.
'"/>




Page: 1

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members of the ... signature of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. ... a 70% tax credit to individuals and corporations which donate directly to a “rural ...
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart is celebrating its grand ... in the Exchange Furniture Mall at 112 Vilseck Road in Fort Stewart. There will ... Plus attendees will have the opportunity to meet general dentists Thomas Richards, DDS, and ...
(Date:4/29/2016)... ... April 29, 2016 , ... World ... the Gyrociser, an exercise invention which aids in proper muscle development. , "The ... CEO and Creative Director of World Patent Marketing. "Globalization has threatened the future ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Reltok Nasal ... and products for the head and neck/ear, nose and throat specialty, has added the ... The KOTLER NASAL AIRWAY™ is a newly patented safety device secured by ...
(Date:4/29/2016)... ... April 29, 2016 , ... CURE Media Group ... patients with cancer, today announced that Lynne Malestic, RN, of Eisenhower Lucy Curci ... Extraordinary Healer® for Oncology Nursing , which honors nurses who have dedicated their ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery systems, ... PIONEERS 2016 conference, presented by Joseph Gunnar & ... New York . Nadav Kidron , CEO ... Presentation Details:   PIONEERS 2016, ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... PARIS , April 27, 2016 ... Year-Over-Year Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) ... today announced its sales for the first quarter ended ... business and the execution of its commercial strategy. ...
Breaking Medicine Technology: